Bayer supports "The Challenge Initiative" of Johns Hopkins Bloomberg School of Public Health with 10 million USD

BayerToday Bayer announced the support of "The Challenge Initiative" ("TCI" hereafter) with a payment of 10 million USD. Hosted at the Johns Hopkins Bloomberg School of Public Health, the initiative provides women and girls living in urban poverty in cities in Africa and Asia with family planning and reproductive health solutions. TCI is led by the Bill & Melinda Gates Institute on Population and Reproductive Health within the Population, Family and Reproductive Health Department at the Johns Hopkins Bloomberg School.

"We have long-standing expertise in supporting family planning worldwide and a strong network on the ground," said Claus Runge, Head of Market Access, Public Affairs & Sustainability at the Pharmaceuticals Division of Bayer. "By empowering women with the freedom of choice with regards to their family planning, especially among the urban poor, this initiative provides a groundbreaking opportunity to create a long-lasting impact in under-served urban communities."

Empowering women by supporting their family planning is an important part of Bayer’s sustainability commitments. By 2030, Bayer aims to provide 100 million women in low- and middle-income countries with access to modern contraception. The initiative announced today contributes to this commitment.

There is a crucial need during the COVID-19 pandemic to maintain family planning programs for women and girls living in urban slums. The initiative strengthens city governments and health systems and at the same time offers a broader platform for integrating COVID-19 prevention and education into its ongoing family planning activities.

TCI's "business unusual" approach allows cities to bring their monetary contributions, ideas and political commitment to the platform and - in return - have access to a challenge fund for additional resources, as well as technical expertise to adopt and scale up high-impact best practices that have been codified for easy adaptation through TCI University. The online "university without walls" alongside a dedicated coaching model has helped TCI continue operating during the COVID-19 pandemic.

About TCI/The Gates Institute

TCI is led by the Bill & Melinda Gates Institute on Population and Reproductive Health within the Population, Family and Reproductive Health Department at the Johns Hopkins Bloomberg School of Public Health. Its implementing partners are Population Services International in India, IntraHealth International in Francophone West Africa, Jhpiego in East Africa and the Johns Hopkins Center for Communication Programs (CCP) in Nigeria.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5 billion euros. Capital expenditures amounted to 2.9 billion euros, R&D expenses to 5.3 billion euros.

Most Popular Now

AstraZeneca COVID-19 vaccine Vaxzevria authorised …

AstraZeneca's COVID-19 vaccine, Vaxzevria (ChAdOx1-S [Recombinant]), formerly AZD1222, has been granted a special approval for emergency use in Japan for active immunisat...

Pfizer and BioNTech to supply the European Union w…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a new agreement with the European Commission (EC) to supply 900 million doses of COMIRNATY®, the companie...

Takeda announces approval of Moderna's COVID-19 va…

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that the Ministry of Health, Labour and Welfare (MHLW) granted special approval under...

Sanofi and GSK initiate global Phase 3 clinical ef…

Today, Sanofi and GlaxoSmithKline plc (GSK) started enrolment in their Phase 3 clinical study to assess the safety, efficacy and immunogenicity of their adjuvanted recomb...

Sanofi and GSK COVID-19 vaccine candidate demonstr…

The Sanofi and GSK adjuvanted recombinant COVID-19 vaccine candidate achieved strong rates of neutralizing antibody responses, in line with those measured in people who h...

European Commission approves Venclyxto-based combi…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Venclyxto® (venetoclax) in combination with hypomethylating agents, azacitidi...

Novartis reaches milestone delivery of 1 billion c…

Novartis announced that it has delivered one billion courses of antimalarial treatment since 1999. More than 90% of this artemisinin-based combination therapy (ACT) was s...

COVID-19 mRNA vaccines are immunogenic in pregnant…

Pregnant women with symptomatic COVID-19 have a higher risk of intensive care unit admissions, mechanical ventilation and death compared to non-pregnant reproductive age ...

Why are some COVID-19 vaccines working better for …

MSU researcher is studying, raising awareness about the role of sex in the efficacy of vaccines that make use of nanomedicine. If there's one take-home message for the...

Rogue antibodies wreak havoc in severe COVID-19 ca…

The development of antibodies to the COVID-19 virus has been the great long-term hope of ending the pandemic. However, immune system turncoats are also major culprits in ...

New vaccine platform: 'Two-one replicon-and-VLP-mi…

To stop the current SARS-CoV-2 pandemic, vaccines of high quality, safety, and efficacy are required. Scientists of the Paul-Ehrlich-Institut and the Ludwig Maximilian Un...

COVID-19 monoclonal antibodies reduce risk of hosp…

Monoclonal antibodies, a COVID-19 treatment given early after coronavirus infection, cut the risk of hospitalization and death by 60% in those most likely to suffer compl...